Literature DB >> 24807491

Potential urine and serum biomarkers for patients with bladder pain syndrome/interstitial cystitis.

Hann-Chorng Kuo1.   

Abstract

There is a lack of consensus on the pathophysiology of bladder pain syndrome/interstitial cystitis. The chronic pain symptoms of bladder pain syndrome/interstitial cystitis refractory to local treatment could be a result of central nervous system sensitization and persisting abnormalities in the bladder wall, which activate the afferent sensory system. Evidence also shows that bladder pain syndrome/interstitial cystitis is a heterogeneous syndrome and that the two subtypes, the ulcerative (classic) and non-ulcerative types, represent different disease entities. There is a need for non-invasive markers for the differential diagnoses of the subtypes of bladder pain syndrome/interstitial cystitis, and between bladder pain syndrome/interstitial cystitis and bladder sensory disorders, such as hypersensitive bladder syndrome or overactive bladder. Bladder pain syndrome/interstitial cystitis, but not overactive bladder, involves an aberrant differentiation program in the bladder urothelium that leads to altered synthesis of several proteoglycans, cell adhesion and tight junction proteins, and bacterial defense molecules. These findings have led to the rationale for identifying urinary biomarkers to detect bladder pain syndrome/interstitial cystitis in patients with frequency urgency syndrome. Recently, the markers that have been the focus of the most research are antiproliferative factor, epidermal growth factor, heparin-binding epidermal growth factor, glycosaminoglycans and bladder nitric oxide. In addition, inflammatory proteins in the urine and serum play important roles in the pathogenesis of bladder pain syndrome/interstitial cystitis. The urinary proteome is an easily accessible source of biomarkers for differentiation between inflammatory bladder disorders. Analysis of multiple urinary proteins and serum cytokines could provide a diagnostic basis for bladder pain syndrome/interstitial cystitis, and could be a tool for the differential diagnosis of bladder pain syndrome/interstitial cystitis and other sensory bladder disorders.
© 2014 The Japanese Urological Association.

Entities:  

Keywords:  biomarker; chemokines; interstitial cystitis; overactive bladder; proteomics

Mesh:

Substances:

Year:  2014        PMID: 24807491     DOI: 10.1111/iju.12311

Source DB:  PubMed          Journal:  Int J Urol        ISSN: 0919-8172            Impact factor:   3.369


  28 in total

Review 1.  [Interstitial cystitis : Diagnosis and pharmacological and surgical therapy].

Authors:  A Gonsior; J Neuhaus; L C Horn; T Bschleipfer; J-U Stolzenburg
Journal:  Urologe A       Date:  2017-06       Impact factor: 0.639

2.  Mesenchymal Stem Cell Therapy Alleviates Interstitial Cystitis by Activating Wnt Signaling Pathway.

Authors:  Miho Song; Jisun Lim; Hwan Yeul Yu; Junsoo Park; Ji-Youn Chun; Jaeho Jeong; Jinbeom Heo; Hyunsook Kang; YongHwan Kim; Yong Mee Cho; Seong Who Kim; Wonil Oh; Soo Jin Choi; Sung-Wuk Jang; Sanghyeok Park; Dong-Myung Shin; Myung-Soo Choo
Journal:  Stem Cells Dev       Date:  2015-04-09       Impact factor: 3.272

3.  An Immunogenic Peptide, T2 Induces Interstitial Cystitis/Painful Bladder Syndrome: an Autoimmune Mouse Model for Interstitial Cystitis/Painful Bladder Syndrome.

Authors:  Li Zhang; Awais Ullah Ihsan; Yanfang Cao; Farhan Ullah Khan; Yijie Cheng; Lei Han; Xiaohui Zhou
Journal:  Inflammation       Date:  2017-12       Impact factor: 4.092

4.  Advances in diagnosis and treatment of interstitial cystitis/painful bladder syndrome.

Authors:  Avinash Chennamsetty; Michael J Ehlert; Kenneth M Peters; Kim A Killinger
Journal:  Curr Infect Dis Rep       Date:  2015-01       Impact factor: 3.725

5.  The Diagnosis of Chronic Pelvic Pain: How Can We Detect Urological Pain?

Authors:  Jung Ki Jo; Yong Tae Kim
Journal:  Int Neurourol J       Date:  2022-06-30       Impact factor: 3.038

Review 6.  Prevalence, Risk Factors, Pathophysiology, Potential Biomarkers and Management of Feline Idiopathic Cystitis: An Update Review.

Authors:  Chengxi He; Kai Fan; Zhihui Hao; Na Tang; Gebin Li; Shuaiyu Wang
Journal:  Front Vet Sci       Date:  2022-06-21

7.  Beta-3 adrenergic receptors could be significant factors for overactive bladder-related symptoms.

Authors:  Fukashi Yamamichi; Katsumi Shigemura; Hosny M Behnsawy; Masuo Yamashita; Toshiro Shirakawa; Masato Fujisawa
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

8.  The Challenges of Interstitial Cystitis: Current Status and Future Prospects.

Authors:  Samuel Belknap; Eric Blalock; Deborah Erickson
Journal:  Drugs       Date:  2015-12       Impact factor: 9.546

Review 9.  Metabolomics insights into pathophysiological mechanisms of interstitial cystitis.

Authors:  Oliver Fiehn; Jayoung Kim
Journal:  Int Neurourol J       Date:  2014-09-24       Impact factor: 2.835

10.  A high molecular weight hyaluronic acid biphasic dispersion as potential therapeutics for interstitial cystitis.

Authors:  Peadar R Rooney; Vijaya Krishna Kannala; Niranjan G Kotla; Ana Benito; Damien Dupin; Iraida Loinaz; Leo R Quinlan; Yury Rochev; Abhay Pandit
Journal:  J Biomed Mater Res B Appl Biomater       Date:  2020-10-26       Impact factor: 3.368

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.